Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.8M
-
Number of holders
-
121
-
Total 13F shares, excl. options
-
19.4M
-
Shares change
-
+2.78M
-
Total reported value, excl. options
-
$298M
-
Value change
-
+$38.2M
-
Put/Call ratio
-
1.83
-
Number of buys
-
75
-
Number of sells
-
-48
-
Price
-
$15.39
Significant Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) as of Q2 2017
171 filings reported holding CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2017.
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) has 121 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.4M shares
of 54.8M outstanding shares and own 35.39% of the company stock.
Largest 10 shareholders include RHO CAPITAL PARTNERS INC (3.57M shares), STATE STREET CORP (3.25M shares), BlackRock Inc. (1.65M shares), FMR LLC (1.2M shares), VANGUARD GROUP INC (1.11M shares), Chescapmanager LLC (1.02M shares), DISCIPLINED GROWTH INVESTORS INC /MN (876K shares), Balyasny Asset Management LLC (525K shares), PRICE T ROWE ASSOCIATES INC /MD/ (473K shares), and FRANKLIN RESOURCES INC (435K shares).
This table shows the top 121 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.